| 0 |
HEPATITIS D ANTIBODY POSITIVE |
1 |
0.5000 |
| 1 |
HEPATITIS D RNA POSITIVE |
3 |
0.3333 |
| 2 |
HEPATITIS D |
6 |
0.0714 |
| 3 |
HEPATIC FIBROSIS MARKER INCREASED |
1 |
0.0333 |
| 4 |
TOTAL BILE ACIDS INCREASED |
2 |
0.0137 |
| 5 |
HEPATITIS B DNA ASSAY POSITIVE |
1 |
0.0078 |
| 6 |
NASAL CYST |
1 |
0.0071 |
| 7 |
INJECTION SITE DERMATITIS |
1 |
0.0069 |
| 8 |
BILE ACIDS INCREASED |
1 |
0.0056 |
| 9 |
SPONTANEOUS BACTERIAL PERITONITIS |
1 |
0.0041 |
| 10 |
INFUSION SITE THROMBOSIS |
1 |
0.0037 |
| 11 |
ASTROCYTOMA |
1 |
0.0025 |
| 12 |
PORTAL HYPERTENSIVE GASTROPATHY |
1 |
0.0018 |
| 13 |
LICHEN PLANUS |
4 |
0.0017 |
| 14 |
BLOOD BILIRUBIN DECREASED |
1 |
0.0016 |
| 15 |
HEPATITIS B DNA INCREASED |
1 |
0.0015 |
| 16 |
CUTANEOUS SYMPTOM |
1 |
0.0015 |
| 17 |
HEPATIC FIBROSIS |
5 |
0.0015 |
| 18 |
ALANINE AMINOTRANSFERASE ABNORMAL |
3 |
0.0014 |
| 19 |
PORTAL HYPERTENSION |
4 |
0.0013 |
| 20 |
BLOOD ALBUMIN INCREASED |
1 |
0.0011 |
| 21 |
VIROLOGIC FAILURE |
6 |
0.0011 |
| 22 |
VIRAL LOAD INCREASED |
4 |
0.0010 |
| 23 |
SUSPECTED PRODUCT CONTAMINATION |
1 |
0.0010 |
| 24 |
LIVER TRANSPLANT |
3 |
0.0008 |
| 25 |
BLOOD BILIRUBIN ABNORMAL |
1 |
0.0008 |
| 26 |
HEPATIC CIRRHOSIS |
14 |
0.0007 |
| 27 |
VIRAEMIA |
1 |
0.0007 |
| 28 |
VARICES OESOPHAGEAL |
2 |
0.0007 |
| 29 |
PORTAL VEIN THROMBOSIS |
2 |
0.0006 |
| 30 |
HYPOMANIA |
2 |
0.0005 |
| 31 |
HEPATOCELLULAR CARCINOMA |
4 |
0.0005 |
| 32 |
VITREOUS DETACHMENT |
1 |
0.0005 |
| 33 |
OESOPHAGEAL VARICES HAEMORRHAGE |
1 |
0.0005 |
| 34 |
CHRONIC GASTRITIS |
1 |
0.0004 |
| 35 |
ACUTE PSYCHOSIS |
1 |
0.0004 |
| 36 |
ABNORMAL UTERINE BLEEDING |
1 |
0.0004 |
| 37 |
DUODENITIS |
1 |
0.0003 |
| 38 |
IMMUNOSUPPRESSANT DRUG LEVEL INCREASED |
1 |
0.0003 |
| 39 |
B-CELL LYMPHOMA |
1 |
0.0003 |
| 40 |
TYPE I HYPERSENSITIVITY |
1 |
0.0003 |
| 41 |
DEPRESSIVE SYMPTOM |
1 |
0.0003 |
| 42 |
CHRONIC SINUSITIS |
1 |
0.0003 |
| 43 |
INTERNATIONAL NORMALISED RATIO DECREASED |
1 |
0.0002 |
| 44 |
SUICIDAL BEHAVIOUR |
1 |
0.0002 |
| 45 |
PANCYTOPENIA |
10 |
0.0002 |
| 46 |
PANCREATITIS ACUTE |
4 |
0.0002 |
| 47 |
PROTHROMBIN TIME PROLONGED |
1 |
0.0002 |
| 48 |
HEPATIC FAILURE |
5 |
0.0002 |
| 49 |
CHOLANGITIS |
1 |
0.0002 |
| 50 |
HEPATITIS ACUTE |
1 |
0.0002 |
| 51 |
METASTASES TO LYMPH NODES |
1 |
0.0001 |
| 52 |
INJURY ASSOCIATED WITH DEVICE |
3 |
0.0001 |
| 53 |
DRUG-INDUCED LIVER INJURY |
4 |
0.0001 |
| 54 |
SHOCK HAEMORRHAGIC |
1 |
0.0001 |
| 55 |
IRON DEFICIENCY ANAEMIA |
1 |
0.0001 |
| 56 |
HEPATIC ENCEPHALOPATHY |
1 |
0.0001 |
| 57 |
APPENDICITIS |
1 |
0.0001 |
| 58 |
VITAMIN D DEFICIENCY |
1 |
0.0001 |
| 59 |
LIVER FUNCTION TEST INCREASED |
2 |
0.0001 |
| 60 |
TREATMENT NONCOMPLIANCE |
5 |
0.0001 |
| 61 |
TRANSAMINASES INCREASED |
2 |
0.0001 |
| 62 |
REBOUND EFFECT |
1 |
0.0001 |
| 63 |
POLYNEUROPATHY |
1 |
0.0001 |
| 64 |
DERMATITIS ALLERGIC |
1 |
0.0001 |
| 65 |
LYMPHOPENIA |
1 |
0.0001 |
| 66 |
VIRAL INFECTION |
2 |
0.0001 |
| 67 |
LEUKOPENIA |
3 |
0.0001 |
| 68 |
HEAD DISCOMFORT |
1 |
0.0001 |
| 69 |
CHOLESTASIS |
1 |
0.0001 |
| 70 |
FULL BLOOD COUNT DECREASED |
1 |
0.0000 |
| 71 |
INJECTION SITE WARMTH |
1 |
0.0000 |
| 72 |
LIVER DISORDER |
2 |
0.0000 |
| 73 |
THROMBOCYTOPENIA |
5 |
0.0000 |
| 74 |
HEPATIC CANCER |
1 |
0.0000 |
| 75 |
LOCALISED INFECTION |
1 |
0.0000 |
| 76 |
INFLUENZA LIKE ILLNESS |
3 |
0.0000 |
| 77 |
RESPIRATORY DISTRESS |
1 |
0.0000 |
| 78 |
INTENTIONAL DOSE OMISSION |
1 |
0.0000 |
| 79 |
EPILEPSY |
1 |
0.0000 |
| 80 |
ALANINE AMINOTRANSFERASE INCREASED |
2 |
0.0000 |
| 81 |
HEPATIC ENZYME INCREASED |
2 |
0.0000 |
| 82 |
INJECTION SITE MASS |
1 |
0.0000 |
| 83 |
HEPATIC FUNCTION ABNORMAL |
1 |
0.0000 |
| 84 |
DISEASE PROGRESSION |
3 |
0.0000 |
| 85 |
MATERNAL EXPOSURE DURING PREGNANCY |
2 |
0.0000 |
| 86 |
NEUTROPENIA |
3 |
0.0000 |
| 87 |
PANCREATITIS |
1 |
0.0000 |
| 88 |
ASTHENIA |
7 |
0.0000 |
| 89 |
DISTURBANCE IN ATTENTION |
1 |
0.0000 |
| 90 |
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION |
1 |
0.0000 |
| 91 |
BONE PAIN |
1 |
0.0000 |
| 92 |
INJECTION SITE PRURITUS |
1 |
0.0000 |
| 93 |
INJECTION SITE REACTION |
1 |
0.0000 |
| 94 |
SLEEP DISORDER |
1 |
0.0000 |
| 95 |
DYSGEUSIA |
1 |
0.0000 |
| 96 |
INJECTION SITE SWELLING |
1 |
0.0000 |
| 97 |
TREATMENT FAILURE |
1 |
0.0000 |
| 98 |
RENAL IMPAIRMENT |
1 |
0.0000 |
| 99 |
COVID-19 |
2 |
0.0000 |
| 100 |
BREAST CANCER |
1 |
0.0000 |
| 101 |
HAEMOGLOBIN DECREASED |
1 |
0.0000 |
| 102 |
HAEMORRHAGE |
1 |
0.0000 |
| 103 |
PLATELET COUNT DECREASED |
1 |
0.0000 |
| 104 |
WHITE BLOOD CELL COUNT DECREASED |
1 |
0.0000 |
| 105 |
INJECTION SITE ERYTHEMA |
1 |
0.0000 |
| 106 |
PRURITUS |
3 |
0.0000 |
| 107 |
PRODUCT QUALITY ISSUE |
1 |
0.0000 |
| 108 |
CONDITION AGGRAVATED |
2 |
0.0000 |
| 109 |
PERIPHERAL SWELLING |
1 |
0.0000 |
| 110 |
FATIGUE |
5 |
0.0000 |
| 111 |
DRUG INTERACTION |
1 |
0.0000 |
| 112 |
URTICARIA |
1 |
0.0000 |
| 113 |
URINARY TRACT INFECTION |
1 |
0.0000 |
| 114 |
HYPERSENSITIVITY |
1 |
0.0000 |
| 115 |
DRUG INEFFECTIVE |
7 |
0.0000 |
| 116 |
BLOOD GLUCOSE INCREASED |
1 |
0.0000 |
| 117 |
OFF LABEL USE |
4 |
0.0000 |
| 118 |
DEPRESSION |
1 |
0.0000 |
| 119 |
DECREASED APPETITE |
1 |
0.0000 |
| 120 |
PRODUCT USE IN UNAPPROVED INDICATION |
1 |
0.0000 |
| 121 |
DYSPNOEA |
2 |
0.0000 |
| 122 |
PRODUCT DOSE OMISSION ISSUE |
1 |
0.0000 |
| 123 |
HEADACHE |
2 |
0.0000 |
| 124 |
PYREXIA |
1 |
0.0000 |
| 125 |
PAIN |
1 |
0.0000 |
| 126 |
NAUSEA |
1 |
0.0000 |
| 127 |
DEATH |
1 |
0.0000 |